CLEC4C

CLEC4C Overview

English NameC-Type lectin domain family 4 member CApproved Drugs0
Drugs in Clinical Trials4Target SynonymDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Highest Development StagePhase 3 Clinical
English NameC-Type lectin domain family 4 member C
Target SynonymDLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Approved Drugs0
Drugs in Clinical Trials4
Highest Development StagePhase 3 Clinical

CLEC4C Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (5)

  • Species

    Human (3)Cynomolgus (2)

  • Tag

    Fc Tag (2)His Tag (2)His Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (4)Biotin-labeled (1)

CLEC4C Background

CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

CLEC4C Synonyms

DLEC,CLEC4C,BDCA-2,CD303,CLECSF11,CLECSF7, HECL

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LitifilimabBIIB-059Phase 3 ClinicalBiogen IncLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
SSGJ-626SSGJ-626; 626Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdLupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
DB-2304DB-2304Phase 1 ClinicalDuality Biologics (Suzhou) Co LtdAutoimmune Diseases
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland